中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2014年
5期
862-863
,共2页
放疗%瘤体局部注射%甘露聚糖肽%宫颈癌
放療%瘤體跼部註射%甘露聚糖肽%宮頸癌
방료%류체국부주사%감로취당태%궁경암
Radiotherapy%Local Injection of Tumor%Mannatide%Cervical Cancer
目的：：探讨在放化疗基础上联合瘤体局部注射甘露聚糖肽治疗宫颈癌的临床疗效。方法：2007年02月~2012年03月期间我院符合上述病例选择标准的宫颈癌患者80例,随机分为治疗组40例,对照组40例,对照患者采用单纯Co照射治疗。治疗组患者采用Co照射治疗的同时,在瘤体局部注射甘露聚糖肽,10mg/d。结果：治疗组总有效率为92.50%,显著高于对照组的85.00%(P=0.29)。治疗组肿瘤全消率为62.50%,显著高于对照组肿瘤全消率40.00%(P=0.044)。治疗组白细胞降低发生率为12.50%,消化道反应发生率为7.50%,均显著低于对照组(P值分别为0.018、0.034)。结论：甘露聚糖肽能有效提高放疗宫颈癌患者肿瘤全消率,提高临床疗效,降低消化道反应、白细胞降低等不良反应发生率。
目的：：探討在放化療基礎上聯閤瘤體跼部註射甘露聚糖肽治療宮頸癌的臨床療效。方法：2007年02月~2012年03月期間我院符閤上述病例選擇標準的宮頸癌患者80例,隨機分為治療組40例,對照組40例,對照患者採用單純Co照射治療。治療組患者採用Co照射治療的同時,在瘤體跼部註射甘露聚糖肽,10mg/d。結果：治療組總有效率為92.50%,顯著高于對照組的85.00%(P=0.29)。治療組腫瘤全消率為62.50%,顯著高于對照組腫瘤全消率40.00%(P=0.044)。治療組白細胞降低髮生率為12.50%,消化道反應髮生率為7.50%,均顯著低于對照組(P值分彆為0.018、0.034)。結論：甘露聚糖肽能有效提高放療宮頸癌患者腫瘤全消率,提高臨床療效,降低消化道反應、白細胞降低等不良反應髮生率。
목적：：탐토재방화료기출상연합류체국부주사감로취당태치료궁경암적림상료효。방법：2007년02월~2012년03월기간아원부합상술병례선택표준적궁경암환자80례,수궤분위치료조40례,대조조40례,대조환자채용단순Co조사치료。치료조환자채용Co조사치료적동시,재류체국부주사감로취당태,10mg/d。결과：치료조총유효솔위92.50%,현저고우대조조적85.00%(P=0.29)。치료조종류전소솔위62.50%,현저고우대조조종류전소솔40.00%(P=0.044)。치료조백세포강저발생솔위12.50%,소화도반응발생솔위7.50%,균현저저우대조조(P치분별위0.018、0.034)。결론：감로취당태능유효제고방료궁경암환자종류전소솔,제고림상료효,강저소화도반응、백세포강저등불량반응발생솔。
Objective:To observe the clinical efficacy of radiotherapy combined with local injection of tumor using Mannatide in treatment of cervical cancer. Methods:80 patients in our hospital meet the selection criteria of cervical cancer from February 2007 to March 2012 period were randomly divided into a treatment group and control group.40 cases in the control group were given Co radiation therapy alone. The treatment group were given additional local injection of tumor using Mannatide 10mg/d. Results:The total effective rate of treatment group and control group were 92.50%and 85.00%(P=0.29). The tumor complete remission rate of treatment group was 62.50%, which was significantly higher than 40.00%of the control group (P=0.044). The incidence of reduction of leukocyte and the incidence of gastrointestinal reactions of the treatment group were 12.50%and 7.50%, both were significantly lower than that of the control group (P=0.018,0.034). Conclusion:Mannatide can improve complete remission rate of cervical cancer patients treated with radiotherapy, improve clinical efficacy and reduce gastrointestinal reactions, such as leukocyte reduced incidence of adverse reactions.
